CBD wholesaler in France: what a professional must check

The framework rests on the decree of 30 December 2021, issued under article R. 5132-86 of the public health code. Its article 1, paragraph I, authorises only those varieties of Cannabis sativa L. whose Δ⁹-THC content does not exceed 0.30% and which are listed in the EU common catalogue of varieties of agricultural plant species or in the official French catalogue.

Three conditions accompany that authorisation and are often forgotten on the buyer's side: flowers and leaves must come from certified seeds, cultivation is reserved for active farmers, and the sale of plants, like the taking of cuttings, remains prohibited.

Paragraph III deserves to be quoted as it stands, because it carries the bulk of the commercial risk: "The delta-9-tetrahydrocannabinol content of hemp extracts, as well as of the products incorporating them, shall not exceed 0.30%." The ceiling therefore covers not only the raw flower, but the extract and any finished product that incorporates it.

The European Commission's hemp page recalls the 0.3% threshold applicable under the Common Agricultural Policy and listed 116 registered varieties in 2024. A useful clarification: the 0.2% figure still found here and there corresponds to the law prior to 2023.

This is the most widespread error in commercial documentation. By its decision no. 444887 of 29 December 2022, the Conseil d'État did not annul the decree. Its operative part annuls paragraph II of article 1, that is, the ban on selling raw flowers and leaves to the consumer. The consolidated version on Légifrance has since displayed "II. (Annulé)", with paragraphs I and III remaining in force.

In other words, the variety rule, the certified-seed requirement and the 0.30% ceiling on extracts all survived the litigation. A supplier who presents the decision as a general liberalisation misdescribes the applicable law.

The Conseil d'État's press release sets out the reasoning: CBD "has no psychotropic effect and does not cause dependence". The court also noted that the THC content could be checked by rapid, inexpensive tests. Analytical proof is therefore the mechanism on which the highest administrative court itself based its decision.

This is today the leading source of risk. In a statement of 20 May 2026, the Ministry of Agriculture recalls that foodstuffs containing CBD among their ingredients are not authorised under Regulation (EU) 2015/2283 on novel foods, the safety of CBD not having been demonstrated.

Only two categories remain lawful as foods: hemp seeds and their derivatives, including seed oil, and leaves intended exclusively for the preparation of an aqueous infusion. Neither may be enriched with cannabinoid extracts. The ministry also announces the extension of checks to all foodstuffs highlighting CBD, food supplements included, via the departmental anti-fraud operational committees.

A point of method for the buyer: this is not a new ban created in 2026, but the generalised enforcement of an earlier rule. Stock acquired before the checks was therefore never lawful as a foodstuff.

The scientific background is public. The EFSA communicated on 9 February 2026 a provisional safe dose of 0.0275 mg per kilogram of body weight per day, roughly 2 mg per day for a 70 kg adult. We detail this shift in our guide to CBD regulation in France.

That leaves as tradeable wholesale: flowers, resins, non-food extracts, vaping products and cosmetics.

A certificate without an identifiable laboratory proves nothing. In France, decree no. 2008-1401 of 19 December 2008 designates the Comité français d'accréditation as the national accreditation body, alone empowered to accredit conformity assessment bodies. Testing laboratories are accredited under standard NF EN ISO/IEC 17025, which covers technical competence and impartiality.

Two concrete checks, rarely performed: note the accreditation number, then verify that the scope indeed covers the quantification of cannabinoids in the matrix concerned. An accreditation holds for a defined scope, not in general.

A point of honesty is required: the decree does not itself impose the use of an accredited laboratory. Accredited analysis is the means of proving compliance with the 0.30%, not a self-standing obligation. Our article on reading a certificate of analysis details the lines to check, and our quality buying guide applies the same grid to retail. The CBD flowers we offer are analysed batch by batch.

We have identified, in the official sources consulted, no specific authorisation regime conditioning the opening of a CBD business. That finding is the result of documentary research, not a legal guarantee: our article on opening a shop gathers the other parameters.

A second useful silence: no legal classification of flower grades exists in French or European law. Commercial mentions of calibre or grade carry no regulatory consequence.

Is a specific licence required to sell CBD in France?

No official source consulted establishes an authorisation regime specific to CBD. The activity apparently falls under the ordinary law of commercial registration. The real obligations concern the product: a variety listed in the catalogue, certified seeds, a Δ⁹-THC content below 0.30%, and compliance with food status.

Can a wholesaler still offer ingestible CBD products?

No. The Ministry of Agriculture recalled on 20 May 2026 that foodstuffs containing CBD are not authorised under Regulation (EU) 2015/2283. Only hemp seeds and their derivatives, along with leaves intended for an aqueous infusion, remain lawful as foods, without cannabinoid enrichment.

Does the 0.30% threshold also apply to extracts and finished products?

Yes. Paragraph III of article 1 of the decree of 30 December 2021 expressly covers hemp extracts and the products incorporating them. That paragraph was not annulled by the Conseil d'État in December 2022: it remains fully applicable, whatever the format sold.